search
Back to results

Melbourne Infant Study - Bacille Calmette Guérin (BCG) for Allergy & Infection Reduction (MIS BAIR)

Primary Purpose

Allergy, Eczema, Respiratory Tract Infections

Status
Active
Phase
Phase 3
Locations
Australia
Study Type
Interventional
Intervention
BCG
Sponsored by
Murdoch Childrens Research Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Allergy focused on measuring BCG, Bacille Calmette Guérin, Allergy, Immunity, Immune response, Vaccine, Infants, Children, Infection

Eligibility Criteria

undefined - 10 Days (Child)All SexesAccepts Healthy Volunteers

Inclusion criteria:

  • Less than 10 days old;
  • English speaking mother;
  • An informed consent form must be signed and dated by their parent(s) or legally acceptable representative after the nature of the study has been explained and prior to any study assessments/procedures;
  • The infant's mother has screened negative for HIV during this pregnancy;
  • Born no earlier than eight weeks before estimated date of delivery;
  • Birth weight >1500g.
  • The legal guardian expects to be able to complete four online/phone questionnaires over the infant's first 12 months of life and for the infant to be available for skin prick testing at RCH between 12-16 months of age.

Exclusion criteria:

  • Any indication for BCG immunisation in the first 12 months of life including:

    • likely travel to a high tuberculosis (TB) incidence country in the first year of life.
    • Aboriginal and Torres Strait Islander babies living in parts of Australia where the incidence of TB is higher
    • newborn babies, if either parent has leprosy or a family history of leprosy
    • newborn in contact with a patient with TB.
  • Known or suspected HIV infection
  • Treatment with corticosteroids or other immunosuppressive therapy, including monoclonal antibodies against tumour necrosis factor-alpha (TNF-alpha) (e.g. infliximab, etanercept, adalimumab).
  • Born to a mother treated with bDMARDS (e.g. TNF-alpha blocking monoclonal antibodies) in the 3rd trimester;
  • Congenital cellular immunodeficiencies including specific deficiencies of the interferon gamma pathway;
  • Malignancies involving bone marrow or lymphoid systems;
  • Serious underlying illness including severe malnutrition;
  • Medically unstable;
  • Generalised septic skin disease and skin conditions such as eczema, dermatitis and psoriasis;
  • Significant febrile illness;
  • Mother immunosuppressed;
  • Family history of immunodeficiency;
  • Consanguineous parents;
  • Multiple births more than twins.

Sites / Locations

  • Mercy Hospital for Women
  • Royal Children's Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

No BCG

BCG

Arm Description

No BCG

Mycobacterium bovis BCG (Bacille Calmette Guérin) vaccine, Danish Strain 1331

Outcomes

Primary Outcome Measures

Atopic sensitisation measured by skin prick test (SPT)
Proportion of participants with a positive SPT defined as wheal diameter ≥2 mm greater than negative control at 15 min to one or more of a panel of food and aeroallergens
Atopic sensitisation measured by skin prick test (SPT)
Proportion of participants with a positive SPT defined as wheal diameter ≥2 mm greater than negative control at 15 min to one or more of a panel of food and aeroallergens
Lower respiratory tract infection (LRTI)
Measured by parent report
Lower respiratory tract infection (LRTI) hospital admissions
Proportion of participants with ≥1 hospital admission for LRTI reported by parent
Eczema ever
Proportion of participants with eczema measured by Williams' UK diagnostic criteria using parental report of symptoms
Eczema ever
Proportion of participants with eczema measured by Williams' UK diagnostic criteria using parental report of symptoms
Current asthma
Using ISAAC definitions
Asthma ever
Using ISAAC definitions

Secondary Outcome Measures

Clinical food allergy
Proportion of participants with challenge-proven food allergy OR convincing history of food allergy in participants with a SPT wheal diameter ≥2 mm greater than negative control at 15 min to one or more of a panel of food allergens
Clinical food allergy
Proportion of participants with challenge-proven food allergy OR convincing history of food allergy in participants with a SPT wheal diameter ≥2 mm greater than negative control at 15 min to one or more of a panel of food allergens
Atopic sensitisation measured by SPT using a more stringent cut-off
Proportion of participants with a positive SPT defined as wheal diameter ≥3 mm greater than negative control at 15 min to one or more of a panel of food allergens and aeroallergens
Atopic sensitisation measured by SPT using a more stringent cut-off
Proportion of participants with a positive SPT defined as wheal diameter ≥3 mm greater than negative control at 15 min to one or more of a panel of food allergens and aeroallergens
Atopic sensitisation to multiple allergens measured by SPT
Proportion of participants with a positive SPT defined as wheal diameter ≥2 mm greater than negative control at 15 min to two or more of a panel of food allergens and aeroallergens
Atopic sensitisation to multiple allergens measured by SPT
Proportion of participants with a positive SPT defined as wheal diameter ≥2 mm greater than negative control at 15 min to two or more of a panel of food allergens and aeroallergens
Parent report of food allergy
Proportion of participants with an allergic reaction to any food reported by parent
Parent report of food allergy
Proportion of participants with an allergic reaction to any food reported by parent
Egg sensitisation
Proportion of participants with a positive SPT defined as wheal diameter ≥2 mm greater than negative control at 15 min to egg allergen
Egg sensitisation
Proportion of participants with a positive SPT defined as wheal diameter ≥2 mm greater than negative control at 15 min to egg allergen
Egg allergy
Proportion of participants with a challenge-proven egg allergy OR convincing history of egg allergy in participants with a SPT wheal diameter ≥2 mm greater than negative control at 15 min to egg
Egg allergy
Proportion of participants with a challenge-proven egg allergy OR convincing history of egg allergy in participants with a SPT wheal diameter ≥2 mm greater than negative control at 15 min to egg
Atopic wheeze
Proportion of participants with a positive SPT defined as wheal diameter ≥2 mm greater than negative control at 15 min to one or more of a panel of food and aeroallergens together with parent-reported wheeze
Atopic wheeze
Proportion of participants with a positive SPT defined as wheal diameter ≥2 mm greater than negative control at 15 min to one or more of a panel of food and aeroallergens together with parent-reported wheeze
Lower respiratory tract infection (LRTI)
Proportion of participants with ≥1 episode of LRTI, by parental report
Lower respiratory tract infection (LRTI)
Proportion of participants with ≥1 episode of LRTI, by parental report
Rate of lower respiratory tract infection (LRTI)
Number of clinical episodes of LRTI, by parental report
Rate of lower respiratory tract infection (LRTI)
Number of clinical episodes of LRTI, by parental report
Rate of lower respiratory tract infection (LRTI)
Number of clinical episodes of LRTI, by parental report
Infections
Hospital admissions for any infection by parental report
Infections
Hospital admissions for any infection by parental report
Infections
Hospital admissions for any infection by parental report
Hospitalisation for respiratory tract infection (RTI)
Proportion of participants with ≥1 hospital admission for a RTI, by parent report
Hospitalisation for respiratory tract infection (RTI)
Proportion of participants with ≥1 hospital admission for a RTI, by parent report
Hospitalisation for respiratory tract infection (RTI)
Proportion of participants with ≥1 hospital admission for a RTI, by parent report
Rate of any infection
Number of clinical episodes of where an infant had symptoms of: wheeze, rattle/rattly chest, fever, runny/blocked nose, cough, or diarrhoea (with vomiting), by parent report
Rate of any infection
Number of clinical episodes of where an infant had symptoms of: wheeze, rattle/rattly chest, fever, runny/blocked nose, cough, or diarrhoea (with vomiting), by parent report
Rate of upper respiratory tract infection (URTI)
Number of clinical episodes of upper respiratory tract infections, by parent report
Rate of upper respiratory tract infection (URTI)
Number of clinical episodes of upper respiratory tract infections, by parent report
Rate of fever
Number of clinical episodes of fever, by parent report
Rate of fever
Number of clinical episodes of fever, by parent report
Diarrhoea
Proportion of participants with ≥1 episodes of diarrhoea
Diarrhoea
Proportion of participants with ≥1 episodes of diarrhoea
Rash with fever
Proportion of participants with ≥1 episodes of rash with fever
Rash with fever
Proportion of participants with ≥1 episodes of rash with fever
Eczema ever
Proportion of participants with eczema measured by a combined eczema measure
Eczema ever
Proportion of participants with eczema measured by a combined eczema measure
Eczema
Proportion of clinician-diagnosed eczema, by parental report
Eczema
Proportion of clinician-diagnosed eczema, by parental report
Eczema onset
Age of onset of eczema, by parental report
Eczema onset
Age of onset of eczema, by parental report
Eczema severity
Measured by parental report (POEM score)
Eczema severity
Measured by clinical assessment (SCORAD)
Eczema severity
Eczema medication use, by parental report
Eczema severity
Measured by parental report (POEM score)
Eczema severity
Measured by clinical assessment (SCORAD)
Eczema severity
Eczema medication use, by parental report
Asthma severity
Measured by asthma control test (ACT), by parental/participant report
Asthma severity
Measured by asthma control test (ACT), by parental/participant report
Asthma severity
Hospital admissions for asthma, by parental report
Laboratory measures of the immune response

Full Information

First Posted
July 21, 2013
Last Updated
September 6, 2023
Sponsor
Murdoch Childrens Research Institute
Collaborators
Royal Children's Hospital, Mercy Hospital for Women, Australia, University of Melbourne
search

1. Study Identification

Unique Protocol Identification Number
NCT01906853
Brief Title
Melbourne Infant Study - Bacille Calmette Guérin (BCG) for Allergy & Infection Reduction
Acronym
MIS BAIR
Official Title
A Randomised, Controlled Trial to Determine if BCG Immunisation at Birth Reduces Allergy and Infection in Infants
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
July 2013 (undefined)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
December 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Murdoch Childrens Research Institute
Collaborators
Royal Children's Hospital, Mercy Hospital for Women, Australia, University of Melbourne

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
To determine if BCG immunisation at birth, compared to no BCG immunisation, leads to a reduction in measures of allergy and infection in the first 12 months of life. To evaluate the immunological mechanisms underlying the non-specific effects of BCG by comparing markers of immunity between the BCG and non-BCG groups.
Detailed Description
There has been a dramatic rise in allergic diseases worldwide since the 1980s. Asthma rates increased first, followed by eczema, allergic rhinitis and, more recently, food allergy - especially in infants and young children. In Australia, the prevalence of allergic disease is particularly high: up to 30% of children are affected, and eczema and asthma are among the most common chronic diseases of childhood. Preventing allergic disease by an immunomodulatory intervention early in life would be a major advance with significant implications for individual health and public health resources. Bacillus Calmette-Guérin (BCG) immunisation is a potential intervention with an established safety profile. This vaccine has powerful non-specific effects on the cellular immune response that potentially prime host immunity away from an allergic pathway. Observational data and one small randomised controlled trial (RCT) suggest that BCG immunisation at birth leads to a substantial reduction in allergic disease - however, there is an absence of level 1 evidence.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Allergy, Eczema, Respiratory Tract Infections
Keywords
BCG, Bacille Calmette Guérin, Allergy, Immunity, Immune response, Vaccine, Infants, Children, Infection

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
1272 (Actual)

8. Arms, Groups, and Interventions

Arm Title
No BCG
Arm Type
No Intervention
Arm Description
No BCG
Arm Title
BCG
Arm Type
Experimental
Arm Description
Mycobacterium bovis BCG (Bacille Calmette Guérin) vaccine, Danish Strain 1331
Intervention Type
Biological
Intervention Name(s)
BCG
Other Intervention Name(s)
BCG vaccine - Denmark strain, BCG Denmark, Statens Serum Institute BCG vaccine, Mycobacterium bovis BCG (Bacille Calmette Guérin), Danish Strain 1331
Primary Outcome Measure Information:
Title
Atopic sensitisation measured by skin prick test (SPT)
Description
Proportion of participants with a positive SPT defined as wheal diameter ≥2 mm greater than negative control at 15 min to one or more of a panel of food and aeroallergens
Time Frame
1 year of age
Title
Atopic sensitisation measured by skin prick test (SPT)
Description
Proportion of participants with a positive SPT defined as wheal diameter ≥2 mm greater than negative control at 15 min to one or more of a panel of food and aeroallergens
Time Frame
5 years of age
Title
Lower respiratory tract infection (LRTI)
Description
Measured by parent report
Time Frame
0-12 months
Title
Lower respiratory tract infection (LRTI) hospital admissions
Description
Proportion of participants with ≥1 hospital admission for LRTI reported by parent
Time Frame
0-5 years of age
Title
Eczema ever
Description
Proportion of participants with eczema measured by Williams' UK diagnostic criteria using parental report of symptoms
Time Frame
0-12 months
Title
Eczema ever
Description
Proportion of participants with eczema measured by Williams' UK diagnostic criteria using parental report of symptoms
Time Frame
0-5 years of age
Title
Current asthma
Description
Using ISAAC definitions
Time Frame
5 years of age
Title
Asthma ever
Description
Using ISAAC definitions
Time Frame
5 years of age
Secondary Outcome Measure Information:
Title
Clinical food allergy
Description
Proportion of participants with challenge-proven food allergy OR convincing history of food allergy in participants with a SPT wheal diameter ≥2 mm greater than negative control at 15 min to one or more of a panel of food allergens
Time Frame
1 year of age
Title
Clinical food allergy
Description
Proportion of participants with challenge-proven food allergy OR convincing history of food allergy in participants with a SPT wheal diameter ≥2 mm greater than negative control at 15 min to one or more of a panel of food allergens
Time Frame
5 years of age
Title
Atopic sensitisation measured by SPT using a more stringent cut-off
Description
Proportion of participants with a positive SPT defined as wheal diameter ≥3 mm greater than negative control at 15 min to one or more of a panel of food allergens and aeroallergens
Time Frame
1 year of age
Title
Atopic sensitisation measured by SPT using a more stringent cut-off
Description
Proportion of participants with a positive SPT defined as wheal diameter ≥3 mm greater than negative control at 15 min to one or more of a panel of food allergens and aeroallergens
Time Frame
5 years of age
Title
Atopic sensitisation to multiple allergens measured by SPT
Description
Proportion of participants with a positive SPT defined as wheal diameter ≥2 mm greater than negative control at 15 min to two or more of a panel of food allergens and aeroallergens
Time Frame
1 year of age
Title
Atopic sensitisation to multiple allergens measured by SPT
Description
Proportion of participants with a positive SPT defined as wheal diameter ≥2 mm greater than negative control at 15 min to two or more of a panel of food allergens and aeroallergens
Time Frame
5 years of age
Title
Parent report of food allergy
Description
Proportion of participants with an allergic reaction to any food reported by parent
Time Frame
0-12 months of age
Title
Parent report of food allergy
Description
Proportion of participants with an allergic reaction to any food reported by parent
Time Frame
0-5 years of age
Title
Egg sensitisation
Description
Proportion of participants with a positive SPT defined as wheal diameter ≥2 mm greater than negative control at 15 min to egg allergen
Time Frame
1 year of age
Title
Egg sensitisation
Description
Proportion of participants with a positive SPT defined as wheal diameter ≥2 mm greater than negative control at 15 min to egg allergen
Time Frame
5 years of age
Title
Egg allergy
Description
Proportion of participants with a challenge-proven egg allergy OR convincing history of egg allergy in participants with a SPT wheal diameter ≥2 mm greater than negative control at 15 min to egg
Time Frame
1 year of age
Title
Egg allergy
Description
Proportion of participants with a challenge-proven egg allergy OR convincing history of egg allergy in participants with a SPT wheal diameter ≥2 mm greater than negative control at 15 min to egg
Time Frame
5 years of age
Title
Atopic wheeze
Description
Proportion of participants with a positive SPT defined as wheal diameter ≥2 mm greater than negative control at 15 min to one or more of a panel of food and aeroallergens together with parent-reported wheeze
Time Frame
1 year of age
Title
Atopic wheeze
Description
Proportion of participants with a positive SPT defined as wheal diameter ≥2 mm greater than negative control at 15 min to one or more of a panel of food and aeroallergens together with parent-reported wheeze
Time Frame
5 years of age
Title
Lower respiratory tract infection (LRTI)
Description
Proportion of participants with ≥1 episode of LRTI, by parental report
Time Frame
Prior to first Diphtheria, Tetanus, Pertussis (DTP) vaccination
Title
Lower respiratory tract infection (LRTI)
Description
Proportion of participants with ≥1 episode of LRTI, by parental report
Time Frame
0-5 years of age
Title
Rate of lower respiratory tract infection (LRTI)
Description
Number of clinical episodes of LRTI, by parental report
Time Frame
0-12 months
Title
Rate of lower respiratory tract infection (LRTI)
Description
Number of clinical episodes of LRTI, by parental report
Time Frame
Prior to first DTP vaccination
Title
Rate of lower respiratory tract infection (LRTI)
Description
Number of clinical episodes of LRTI, by parental report
Time Frame
0-5 years of age
Title
Infections
Description
Hospital admissions for any infection by parental report
Time Frame
0-12 months
Title
Infections
Description
Hospital admissions for any infection by parental report
Time Frame
Prior to first DTP vaccination
Title
Infections
Description
Hospital admissions for any infection by parental report
Time Frame
0-5 years of age
Title
Hospitalisation for respiratory tract infection (RTI)
Description
Proportion of participants with ≥1 hospital admission for a RTI, by parent report
Time Frame
0-12 months of age
Title
Hospitalisation for respiratory tract infection (RTI)
Description
Proportion of participants with ≥1 hospital admission for a RTI, by parent report
Time Frame
Prior to first DTP vaccination
Title
Hospitalisation for respiratory tract infection (RTI)
Description
Proportion of participants with ≥1 hospital admission for a RTI, by parent report
Time Frame
0-5 years of age
Title
Rate of any infection
Description
Number of clinical episodes of where an infant had symptoms of: wheeze, rattle/rattly chest, fever, runny/blocked nose, cough, or diarrhoea (with vomiting), by parent report
Time Frame
0-12 months of age
Title
Rate of any infection
Description
Number of clinical episodes of where an infant had symptoms of: wheeze, rattle/rattly chest, fever, runny/blocked nose, cough, or diarrhoea (with vomiting), by parent report
Time Frame
Prior to first DTP vaccination
Title
Rate of upper respiratory tract infection (URTI)
Description
Number of clinical episodes of upper respiratory tract infections, by parent report
Time Frame
0-12 months of age
Title
Rate of upper respiratory tract infection (URTI)
Description
Number of clinical episodes of upper respiratory tract infections, by parent report
Time Frame
Prior to first DTP vaccination
Title
Rate of fever
Description
Number of clinical episodes of fever, by parent report
Time Frame
0-12 months of age
Title
Rate of fever
Description
Number of clinical episodes of fever, by parent report
Time Frame
Prior to first DTP vaccination
Title
Diarrhoea
Description
Proportion of participants with ≥1 episodes of diarrhoea
Time Frame
0-12 months of age
Title
Diarrhoea
Description
Proportion of participants with ≥1 episodes of diarrhoea
Time Frame
Prior to first DTP vaccination
Title
Rash with fever
Description
Proportion of participants with ≥1 episodes of rash with fever
Time Frame
0-12 months of age
Title
Rash with fever
Description
Proportion of participants with ≥1 episodes of rash with fever
Time Frame
Prior to first DTP vaccination
Title
Eczema ever
Description
Proportion of participants with eczema measured by a combined eczema measure
Time Frame
0-12 months of age
Title
Eczema ever
Description
Proportion of participants with eczema measured by a combined eczema measure
Time Frame
0-5 years of age
Title
Eczema
Description
Proportion of clinician-diagnosed eczema, by parental report
Time Frame
0-12 months
Title
Eczema
Description
Proportion of clinician-diagnosed eczema, by parental report
Time Frame
0-5 years of age
Title
Eczema onset
Description
Age of onset of eczema, by parental report
Time Frame
0-12 months
Title
Eczema onset
Description
Age of onset of eczema, by parental report
Time Frame
0-5 years of age
Title
Eczema severity
Description
Measured by parental report (POEM score)
Time Frame
0-12 months
Title
Eczema severity
Description
Measured by clinical assessment (SCORAD)
Time Frame
0-12 months
Title
Eczema severity
Description
Eczema medication use, by parental report
Time Frame
0-12 months
Title
Eczema severity
Description
Measured by parental report (POEM score)
Time Frame
0-5 years of age
Title
Eczema severity
Description
Measured by clinical assessment (SCORAD)
Time Frame
0-5 years of age
Title
Eczema severity
Description
Eczema medication use, by parental report
Time Frame
0-5 years of age
Title
Asthma severity
Description
Measured by asthma control test (ACT), by parental/participant report
Time Frame
4 years of age
Title
Asthma severity
Description
Measured by asthma control test (ACT), by parental/participant report
Time Frame
5 years of age
Title
Asthma severity
Description
Hospital admissions for asthma, by parental report
Time Frame
2-5 years of age
Title
Laboratory measures of the immune response
Time Frame
Time Frame: 0-5 years of age
Other Pre-specified Outcome Measures:
Title
Effect of sex on the non-specific effects BCG
Description
Sub-group analysis
Time Frame
0-12 months and 0-5 years of age
Title
Effect of maternal BCG on the non-specific effects BCG
Description
Sub-group analysis
Time Frame
0-12 months and 0-5 years of age
Title
Effect of presence or absence BCG scar on the non-specific effects of BCG
Description
Sub-group analysis
Time Frame
0-12 months and 0-5 years of age
Title
Effect of timing of BCG administration on the non-specific effects BCG
Description
Sub-group analysis
Time Frame
0-12 months and 0-5 years of age
Title
Effect of mode of delivery on the non-specific effects BCG
Description
Sub-group analysis
Time Frame
0-12 months and 0-5 years of age
Title
Effect of family history of allergy on the allergy and eczema outcomes
Description
Sub-group analysis
Time Frame
0-12 months and 0-5 years of age
Title
Effect of season of birth on the non-specific effects BCG
Description
Sub-group analysis
Time Frame
0-12 months and 0-5 years of age
Title
Effect of hepatitis B vaccine timing birth on the non-specific effects BCG
Description
Sub-group analysis
Time Frame
0-12 months and 0-5 years of age
Title
Meta-analysis
Description
Joint meta-analysis with data from the Danish Calmette study (NCT01694108)
Time Frame
36 months
Title
Morbidity
Description
Hospital admissions for any reason by parental report
Time Frame
0-12 months of age
Title
Morbidity
Description
Hospital admissions for any reason by parental report
Time Frame
0-5 years of age

10. Eligibility

Sex
All
Maximum Age & Unit of Time
10 Days
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria: Less than 10 days old; English speaking mother; An informed consent form must be signed and dated by their parent(s) or legally acceptable representative after the nature of the study has been explained and prior to any study assessments/procedures; The infant's mother has screened negative for HIV during this pregnancy; Born no earlier than eight weeks before estimated date of delivery; Birth weight >1500g. The legal guardian expects to be able to complete four online/phone questionnaires over the infant's first 12 months of life and for the infant to be available for skin prick testing at RCH between 12-16 months of age. Exclusion criteria: Any indication for BCG immunisation in the first 12 months of life including: likely travel to a high tuberculosis (TB) incidence country in the first year of life. Aboriginal and Torres Strait Islander babies living in parts of Australia where the incidence of TB is higher newborn babies, if either parent has leprosy or a family history of leprosy newborn in contact with a patient with TB. Known or suspected HIV infection Treatment with corticosteroids or other immunosuppressive therapy, including monoclonal antibodies against tumour necrosis factor-alpha (TNF-alpha) (e.g. infliximab, etanercept, adalimumab). Born to a mother treated with bDMARDS (e.g. TNF-alpha blocking monoclonal antibodies) in the 3rd trimester; Congenital cellular immunodeficiencies including specific deficiencies of the interferon gamma pathway; Malignancies involving bone marrow or lymphoid systems; Serious underlying illness including severe malnutrition; Medically unstable; Generalised septic skin disease and skin conditions such as eczema, dermatitis and psoriasis; Significant febrile illness; Mother immunosuppressed; Family history of immunodeficiency; Consanguineous parents; Multiple births more than twins.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Prof Nigel Curtis, MBBS DCH DTM&H MRCP FRCPCH PhD
Organizational Affiliation
Murdoch Children's Research Institute, Royal Children's Hospital, University of Melbourne
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mercy Hospital for Women
City
Heidelberg
State/Province
Victoria
ZIP/Postal Code
3084
Country
Australia
Facility Name
Royal Children's Hospital
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3052
Country
Australia

12. IPD Sharing Statement

Citations:
PubMed Identifier
35170523
Citation
Pittet LF, Messina NL, Gardiner K, Freyne B, Abruzzo V, Morrison C, Vuillermin P, Allen KJ, Ponsonby AL, Robins-Browne R, Shann F, Flanagan KL, Donath S, Casalaz D, Phillips R, Curtis N. Discordance Between Diagnosis Tools for Assessing Eczema in Infants: A Challenge for Intervention Trials. Dermatitis. 2022 May-Jun 01;33(3):207-214. doi: 10.1097/DER.0000000000000842. Epub 2022 Feb 16.
Results Reference
derived
PubMed Identifier
34309859
Citation
Pittet LF, Messina NL, Gardiner K, Freyne B, Abruzzo V, Francis KL, Morrison C, Zufferey C, Vuillermin P, Allen KJ, Ponsonby AL, Robins-Browne R, Shann F, Flanagan KL, Phillips R, Donath S, Casalaz D, Curtis N. Prevention of infant eczema by neonatal Bacillus Calmette-Guerin vaccination: The MIS BAIR randomized controlled trial. Allergy. 2022 Mar;77(3):956-965. doi: 10.1111/all.15022. Epub 2021 Aug 9.
Results Reference
derived
PubMed Identifier
32544459
Citation
Cirovic B, de Bree LCJ, Groh L, Blok BA, Chan J, van der Velden WJFM, Bremmers MEJ, van Crevel R, Handler K, Picelli S, Schulte-Schrepping J, Klee K, Oosting M, Koeken VACM, van Ingen J, Li Y, Benn CS, Schultze JL, Joosten LAB, Curtis N, Netea MG, Schlitzer A. BCG Vaccination in Humans Elicits Trained Immunity via the Hematopoietic Progenitor Compartment. Cell Host Microbe. 2020 Aug 12;28(2):322-334.e5. doi: 10.1016/j.chom.2020.05.014. Epub 2020 Jun 15.
Results Reference
derived
PubMed Identifier
31843845
Citation
Messina NL, Gardiner K, Donath S, Flanagan K, Ponsonby AL, Shann F, Robins-Browne R, Freyne B, Abruzzo V, Morison C, Cox L, Germano S, Zufferey C, Zimmermann P, Allen KJ, Vuillermin P, South M, Casalaz D, Curtis N. Study protocol for the Melbourne Infant Study: BCG for Allergy and Infection Reduction (MIS BAIR), a randomised controlled trial to determine the non-specific effects of neonatal BCG vaccination in a low-mortality setting. BMJ Open. 2019 Dec 15;9(12):e032844. doi: 10.1136/bmjopen-2019-032844.
Results Reference
derived
PubMed Identifier
30791143
Citation
Zimmermann P, Perrett KP, van der Klis FR, Curtis N. The immunomodulatory effects of measles-mumps-rubella vaccination on persistence of heterologous vaccine responses. Immunol Cell Biol. 2019 Jul;97(6):577-585. doi: 10.1111/imcb.12246. Epub 2019 Mar 28.
Results Reference
derived

Learn more about this trial

Melbourne Infant Study - Bacille Calmette Guérin (BCG) for Allergy & Infection Reduction

We'll reach out to this number within 24 hrs